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Abstract
Mesenchymal stem cells (MSCs) are emerging as key players in regenerative 
medicine for the treatment of various diseases associated with the inflammation 
and degeneration, thereby aiding in therapeutic advancements. Several tissues 
have been identified as potential sources of MSCs including the bone marrow, 
cord blood, dental pulp, umbilical cord, adipose tissue, peripheral blood, and fetal 
liver, of which some are clinically recognized. MSCs are capable of differentiating 
into cells of multiple lineages and therefore established as suitable candidates for 
transplantation in damaged organs. They have added advantage of higher prolifera-
tion, easy expansion, and, more importantly, the absence of HLA class II receptors, 
with potential applications extending toward allogenic settings. MSCs are actively 
involved in different mechanisms related to repair and regeneration of tissues via 
immunomodulation, transdifferentiation, paracrine factors, etc. They are known 
to exhibit profound immunomodulatory effect on T and B cells and natural killer 
(NK) cells mediated via soluble factors and direct cell-cell contact. The MSCs 
activate the immune responses and inhibit proliferation, maturation, and differen-
tiation of T and B cells. The MSC-activated immune responses induce the expres-
sion of regulatory T cells (Tregs). A plethora of studies have established that MSCs 
suppress immune responses via immunomodulation that makes them a preferred 
cell source for the use in clinical trials.
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1. Introduction
Stem cells are undifferentiated cells possessing greater capacity of self-renewal 
and multilineage differentiation potential. This makes them unique candidates for 
curing a diverse variety of human degenerative diseases. Based on their potency, 
stem cells are classified into three broad groups: embryonic stem cells (ESCs), 
fetal stem cells (FSCs), and adult stem cells (ASC). ESCs are pluripotent stem 
cells isolated from inner cell mass of blastocysts of human embryos. The unique-
ness of ESCs lies in the fact that they are capable of differentiation into all three 
primary germ layers, i.e., ectoderm, endoderm, and mesoderm. However, due to 
high tendency of teratoma formation and ethical issues regarding the destruction 
of human embryos, the clinical applications of ESCs are restricted. Alternatively, 
fetal and adult tissue-derived stem cells are gaining popularity with little ethical 
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concerns. Fetal stem cells can be isolated from extraembryonic tissues like cord 
blood, amniotic fluid, Wharton’s jelly, the placenta, and amniotic membrane [1–3]. 
However, adult stem cells (ASCs) are multipotent cells and are usually harvested 
from the bone marrow, adipose tissue, dental pulp, etc. All together, these cells pos-
sess clonogenic and self-renewing potential and plasticity to differentiate and often 
transdifferentiate into different tissue types.
Isolated stem cells from both adult and fetal tissues are multipotent and are rec-
ognized as MSCs. Notably, despite similar morphology and phenotypic properties, 
these tissue-specific MSCs have subtle differences in their regenerative potential due 
to the impact of stem cell niche on cell fate, known as stem cell niche theory, genetic 
variability, and/or epigenetic alterations [4]. Several studies have been carried out 
to show that there are differences in regenerative capacity of MSCs populations of 
Figure 1. 
A diagrammatic representation of cellular characteristics, mode of action, and their therapeutic potential of 
mesenchymal stem cells with current status of clinical trial.
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the same passage number that have been isolated from different pockets of the body 
[5]. A recent comprehensive report also supports the hypothesis that tissue-specific 
MSCs express certain source-specific markers [6]. Dominic et al. established criteria 
to define MSCs on the basis of the following characteristics: (1) plastic-adherent 
cells; (2) expression of surface markers, CD73, CD90, CD105, and HLA-ABC, but 
negative expression from hematopoietic lineage-specific markers, CD34, CD45, 
CD14, CD11b, CD19, or HLA-DR; and (3) potential to differentiate into trilineage, 
i.e., osteoblast, adipocytes, and chondrocytes [7].
Due to their enhanced regenerative potential, the use of MSCs has become 
an emerging strategy for the treatment of injured or degenerated tissues. It was 
observed that in in vivo scenario, MSCs showed profound immunomodulatory 
effect [8]. The most important characteristic of MSCs is its immunomodula-
tory property which augments and modulates both adaptive and innate immune 
responses as it initiates the wound healing paradigm.
MSCs are also known for their immune-privileged property due to their low 
immunogenicity. Human MSCs show low levels of human leukocyte antigen (HLA) 
class I, and they do not express HLA-DR which is necessary to escape immune 
surveillance. The presence of HLA class I is important as low levels of HLA class 
I protect cells from the natural killer (NK) cell-mediated cytotoxicity. On the 
contrary, cells which do not express HLA class I are targeted and destroyed easily. 
Another essential characteristic is that they home and migrate to the site of damage 
where there is secretion of inflammatory chemokines. These events are mediated 
by several chemokine receptors which aid in their migration and homing potential 
to the sites of inflammation [9]. Owing to the immune tolerance property of MSCs, 
they possess several clinical advantages due to which these cells are also referred as 
“universal donors” [10, 11]. However, as true with any other cell-based therapy, the 
evaluation of safety and efficacy of these MSCs in allogeneic strategies for clinical 
use is of utmost importance (Figure 1).
The initial reports of immunoregulatory properties were started with bone 
marrow-derived MSCs (BM-MSCs) [12]. Later, other sources of MSCs such as 
adipose tissue-derived MSCs (AD-MSCs) and Wharton’s jelly-derived MSCs 
(WJ-MSCs) were also explored for their immunomodulatory properties [1].
However, several challenges need to be overcome prior to the clinical appli-
cations of MSCs. Hence, a thorough insight of the various biological proper-
ties of MSCs will elucidate the mechanisms of MSC-based transplantation for 
immunomodulation.
2.  Immunoregulatory function of MSCs in the inflammatory 
microenvironment
A key factor of survival in multicellular organisms is the maintenance and 
balance of homeostatic state. In the absence of inflammation, phagocytic cell is 
recruited to remove the apoptotic cells, whereas during acute injury, it is accom-
panied by inflammation, and the cell components that are released from necrotic 
cells result in microvascular damage due to increased vasopermeability and infiltra-
tion of macrophages and neutrophils [13]. During the process of phagocytosis of 
necrotic cells, there is secretion of pro-inflammatory mediators such as interleu-
kin-1 (IL-1), interferon-γ (IFN-γ), and tumor necrosis factor-α (TNF-α), various 
chemokines which further initiate downstream signaling pathways [14]. Adaptive 
immune response actively participates in the repair of damaged tissues in close asso-
ciation with CD4+, CD8+, T, and B cells [13]. Recently, MSCs have been recognized 
to be actively involved in damaged tissue repair processes. As a functional unit for 
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development and regeneration in various tissues, they hold utmost importance in 
maintaining proper functioning of tissues [15, 16]. In their undifferentiated and 
self-renewable state, the balance among interaction and protection of MSCs appears 
to be achieved by maintaining the stem cells in a specialized microenvironment 
called “niche.” This niche provides accommodation to different molecules to brace 
and coordinate stem cell activities pertaining to growth, proliferation, differentia-
tion, and functionality. In particular, cell-cell interaction in the niche provides 
structural support, regulates adhesive interaction, and activates signals by secretion 
of certain molecules that can control stem cell functions. Stem cell immunoregula-
tory responses occur due to its close association with vasculature which provides 
metabolic cues and a conduit due to which inflammatory cytokines and immune 
cells, as well as humoral factors, can be delivered to the niche. In addition, the niche 
also provides biochemical and biomechanical parameters such as temperature, 
shear force, and chemical signals, which also influence stem cell behavior and fate 
in response to the external environment. In the process of tissue repair, MSCs are 
able to affect the inflamed microenvironment by secreting a cascade of various 
adhesion molecules, growth factors, and pro- and anti-inflammatory cytokines 
[17]. Since MSCs display notable immunomodulatory properties and they are 
able to dodge the immune system recognition mechanisms, they can potentially 
modulate the defense mechanisms of the host. In inflammatory condition, MSCs 
located in immediate location or originating from the bone marrow region start 
migrating to the site of injury. At the site, these MSCs associate themselves closely 
with numerous types of immune cells in order to initiate regeneration process 
of damaged tissue, which is typically accompanied with cytokine storm. The 
combinational sensitization of MSCs by IFN-γ and TNF-α induces the release of 
chemokines where they participate in chemotaxis and are able to inhibit prolifera-
tion of inflammatory effector cells. Several molecules participate in the activation, 
homing, and functionality of MSCs [18] (Figure 2). The commencement of homing 
process is led by selectins present on the endothelium. Specifically, for bone marrow 
homing, the expression of hematopoietic cell E-/L-selectin ligand (HCELL) is very 
important which is a functional glycoform of CD44 present on the migrating cells, 
while MSCs do not express HCELL but express CD44. The subsequent molecules 
participated in the activation of MSCs are mainly chemokine receptors [19, 20].
Chemokines are defined as positively charged short peptides (7–13 kDa). 
Broadly, four families of chemokines have been recognized: CCL family with 
adjacent cysteine residues, CXCL family with cysteine residues separated by a 
single amino acid, CXCL family with two instead of four cysteines, and CX3CL 
family with cysteines separated by three amino acids. For MSCs to home to injury 
site, these cells bear chemokine receptors and are identified at site of injury due to 
production of the chemokines. Hence a thorough understanding of the function-
ing of chemokine receptor profile is important for optimizing the process of both 
internal and external homing processes of MSCs to wound site. The site of injury 
produces abundant chemokines which may provide signal to MSCs or may function 
as chemoattractants [21]. During the process of regeneration or repair, the injury 
site tightly regulates the process of chemokine expression profile or expression 
pattern of each chemokine, which plays a unique role in directed migration of 
cells toward the site of injury. The subsequent expression of chemokines to attract 
specific immune cell types is conducted by immune response of injury.
Integrins are key players associated with the balance activation-dependent 
arrest of MSCs in the second last step of homing. They are known for cell-cell 
mediated matrix and adhesion, and they belong to the largest family of receptors. 
Mammals contain 18α and 18β subunits of integrin that combine to form at least 24 
different heterodimers, each of which corresponds to a specific set of cell surface, 
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extracellular matrix (ECM) or soluble protein ligands. They are multifaceted 
receptors, transmitting bidirectional signals across the cell membrane, which is 
crucial for building a suitable interaction between the exterior and interior of the 
cell. Numerous cell processes like morphology, migration, proliferation, differen-
tiation, and apoptosis are unexpected on this recurrent discussion. According to 
few reports, it was suggested that MSC homing will be affected if integrin-β1 is 
inhibited. Also, interaction of vascular cell adhesion molecule-1-very late antigen-4 
(VCAM1-VL4) is involved functionally in MSC homing [22].
During the last stage of transmigration across the endothelial cell layer and 
below the basement membrane, various lytic enzymes are essential to cleave com-
ponents of the basement membrane, such as the matrix metalloproteinases (MMPs) 
[23]. Specifically, gelatinases, MMP-2 and MMP-9, preferentially degrade collagen 
and gelatin, two of the major components of the basement membrane which facili-
tate MSC migration. The MSCs reportedly help migrate MMP-2 and tissue inhibitor 
of metalloproteinases 3 (TIMP-3) [23].
The initial reports pointing to MSC homing were toward investigating the origin 
of BM-MSCs after allogeneic bone marrow transplantation. Those studies also 
concluded that the hematopoietic cell population was provided by the donor, but 
Figure 2. 
Immunoregulatory action of MSCs at chronic inflammation (left panel) versus acute inflammation (right 
panel). MSCs home to the injury site due to local cytokine storm secreted by activated immune cells. Activation 
and migration of MSCs lead to secretion of multiple immunomodulatory and growth factors. Depending on the 
cytokine signal (acute versus chronic inflammation), MSCs initiate the immunoregulatory response and repair 
the injury site or are unable to inhibit the persisting chronic inflammatory signals resulting in cellular fibrosis.
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the stem cells were provided by the recipient [24]. Therefore, a number of trials at 
both the preclinical and clinical levels have been carried out, and MSCs are seen to 
help migrate in a variety of tissues. Initial studies in animal models also confirmed 
that the presence of MSCs transplanted to donor was present in the bone marrow, 
thymus, spleen, and liver [12, 24, 25].
To elucidate the dynamics of MSCs migration, a systemic infusion of MSCs was 
studied by using varied techniques, i.e., after infusion of MSCs, they were first 
trapped in the lungs, and eventually, the cells disappear from the lungs and are 
distributed to other organs. Other aspects of MSCs homing was also studied by few 
groups under which they studied the factors such as early cell passage, irradiation 
and younger animals and observed that they influence the short-term bone marrow 
homing and condition which in result increases the homing [26–30].
Once MSCs are activated and recruited to the site of injury, there is onset of 
T-cell activation because of the presence of various pro-inflammatory cytokines 
such as IFN-γ, TNF-α, IL-1β, etc. IFN-γ is a critical player in providing stimula-
tory signals for activation and expansion of T cells and its subsets, such as it 
begins to suppress the T cell proliferation, differentiation, and inhibition of 
various biological functions. Other than IFN-γ, TNF-α and IL-1β also activate 
MSCs, either in synergy or alone. After stimulation with pro-inflammatory 
cytokines, MSCs also release other significant immunomodulatory factors. These 
stimulated cells modulate many immune effecters in vitro as well as in an animal 
model [31, 32].
3.  Secretion of anti-inflammatory factors by MSCs is regulated by  
pro-inflammatory cytokines
To participate in tissue repair, MSCs must be in close association with several 
stromal and immune cells. The mode of action of MSC tissue repair is complex 
wherein MSC-derived immunoregulatory factors play a critical role.
MSCs are reported to release an array of growth factors and immunomodulatory 
molecules (Table 1).
To investigate how the inflammatory microenvironment modulated secretion 
of anti-inflammatory factors at the sites of tissue damage and it was concluded that 
MSC-mediated immunosuppression occurs in the microenvironment surrounding 
the MSCs: the inflammatory factors produced during the immune response act to 
turn on the immunosuppressive capacity of MSCs. For example, during pregnancy, 
the developed immunological tolerance along with the fetus development highlights 
the key role of fetus-derived MSCs. These pleotropic cells inhibit a group of cells 
involved in innate and adaptive immunity such as B cells, dendritic cells (DC), 
macrophages, and various effector cells such as NK, CD4+ T, CD8+ T, regulatory T 
(Treg), and NKT cells [33, 34]. The contribution of MSC-derived molecules toward 
the immunoregulation has been discussed (Figure 3).
3.1 Indoleamine-2,3-dioxygenase (IDO)
Indoleamine-2,3-dioxygenase is a mammalian cytosolic enzyme responsible for 
catalyzing the initial step in tryptophan catabolism via the kynurenine degrada-
tion pathways. IDO is comprised of two alpha helical domains with a heme group 
located between them and is an essential amino acid which catalyzes the rate-
limiting step in the degradation of tryptophan, with the kynurenine pathway [35]. 
Any reduction in the concentration of local tryptophan or its metabolite results in 
immunomodulatory effect by IDO expressing cells.
7Mesenchymal Stem Cells Modulate the Immune System in Developing Therapeutic Interventions
DOI: http://dx.doi.org/10.5772/intechopen.80772
Table 1. 
Secretome profile of hMSCs and their functions.
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The studies carried out with placental cells showed that they are capable of 
preventing maternal T-cell destruction of the fetus during pregnancy, which hap-
pens due to the expression of IDO in placental cells. During pregnancy, the fetus 
expresses paternal antigens that do not provoke rejection by the mother like other 
semi-allogeneic grafts [36, 37]. Dendritic cells can also express IDO and thus induce 
a tolerogenic response. Su et al. suggest that MSCs do not have the innate ability to 
express IDO but gain this ability following stimulation by the pro-inflammatory 
cytokines IFN-γ and TNF-α in combination with IL-1β [38]. Recently, the role of 
IDO in MSC-mediated immunoregulation has been demonstrated in the suppres-
sion of various immune cell populations, including T cells and NK cells [39, 40].
3.2 Human leukocyte antigen-G (HLA-G)
HLA-G is a major histocompatibility complex class I antigen encoded by a 
gene on chromosome 6p21. It differs from classical HLA class I molecules by its 
restricted tissue distribution and limited polymorphism in the coding region. 
HLA-G can be expressed as seven distinct protein isoforms, each encoded by a 
specific, alternatively spliced transcript. Four isoforms are membrane-bound 
proteins (HLA-G1, HLA-G2, HLA-G3, and HLA-G4), and the other three isoforms 
are soluble proteins (HLA-G5, HLA-G6, and HLA-G7) [41]. It exerts its immuno-
modulatory functions by interacting with multiple receptors such as LILRB1(ILT2/
CD85j), LILRB2 (ILT4/CD85d), and KIR2DL4 (CD158d) which are differentially 
expressed by immune cells. Besides these receptors, HLA-G can also bind to CD8 
without T-cell receptor (TCR) interaction, provoking NK cells and activated 
CD8 + T cell-induced apoptosis as well as FASL upregulation and secretion [42, 
43]. HLA-G plays a fundamental role in maternal tolerance and transplantation. 
HLA-G expression by MSCs can be positively modulated by IL-10 and leukemia 
inhibitory factor (LIF). Other molecules such as glucocorticoid and interferon-β 
(IFN-β) are found to regulate HLA-G expression in immune cells. HLA-G has been 
Figure 3. 
Representative image shows the immune response of MSCs by secretion of IM factors (left panel). 
Immunoregulatory function of MSCs on different cell types of the innate and adaptive immune cells. (Right panel) 
paracrine effect of MSCs through secretion of exosomes and their fusion with the target cell membrane and release 
of the biological active content for immunomodulatory effect.
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investigated for allogeneic solid organ transplantation and has been well associated 
with reduced number of immune rejection cases in kidney and liver allogeneic 
transplantations [44, 45].
3.3 Prostaglandin E2 (PGE-2)
Prostaglandins are small molecule derivatives of arachidonic acid (AA), pro-
duced by cyclooxygenase (COX, constitutively active cyclooxygenase COX1 and 
inducible COX2) and PG synthases. It can be produced by all cell types of the 
body, with epithelia, fibroblast, and infiltrating inflammatory cells representing 
the major sources of PGE-2 in the course of an immune response. The receptors 
of PGE2 (EP1–EP4) are present on multiple cell types, reflecting the ubiquitous 
function of PGE-2. It is relatively stable in vitro although its decay is accelerated by 
albumin [46]. In contrast, PGE-2 has a very rapid throughput rate in in vivo condi-
tions and is quickly eliminated from tissues and circulation. This property of PGE-2 
is most likely to contribute toward immune pathology and constitutes a potential 
target for immunomodulation. It is worth noting that the effect of PGE-2 in MSC-
mediated immunoregulation in most cases is exerted in combination with other 
immunosuppressive molecules. With human MSCs, PGE-2 has been found to 
act with IDO to alter T-cell proliferation, during proliferation, cytotoxicity, and 
cytokine production by NK cells [47].
3.4 Inducible nitric oxide synthase (iNOs)
Nitric oxide synthases are family of enzymes catalyzing the production of 
nitric oxide from L-arginine. The enzymes convert arginine into citrulline and 
produce NO in the process. NO activity is independent of the level of calcium in the 
cell. However, its activity as other NO isoforms is dependent upon the binding of 
calmodulin (CaM). NO in high concentration is known to inhibit immune responses 
through mechanisms that remain largely unidentified. In addition, upon induction 
cytokines such as TNF-α and IFN-γ, alone or in combination, stimulate NO. This 
has a significant impact on both primary and secondary immune responses. For 
example, NO targets dendritic cells (DCs) that have a crucial role in making 
powerful immune response. It was found to prevent maturation of rat lung DCs 
by inhibiting granulocyte-macrophage colony-stimulating factors. Similarly, NO 
inhibits TNF-α and prevents DC maturation in humans [48]. MSCs produce large 
amounts of chemokines and adhesion molecules; immune cells accumulate in close 
proximity to the MSCs, where the high concentration of secreted NO can suppress 
the immune cells [49, 50].
3.5 Interleukin 10 (IL-10)
IL-10 is produced by both myeloid and lymphoid cells. While it is good immune 
suppressor, it has some immune stimulatory effects. IL-10 is recognized by its 
effect on T cells, macrophages, and monocytes which ultimately prohibit inflam-
matory responses. Thus, it regulates growth and differentiation of B cells, T cells, 
NK cells, and other cells of the immune system hence influencing inflammatory 
responses. IL-10 has the capability to inhibit the production of IL-2, TNF-α, IL-12, 
and IFN-γ. Furthermore, it will downregulate HLA class I. Although IL-10 has 
been implicated in MSC-mediated immunosuppression, direct IL-10 production 
by MSCs has not been demonstrated so far. Instead, contact of antigen-presenting 
cells such as dendritic cells or monocytes with MSCs has been found to induce 
IL-10 production [51–53].
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3.6 Other mediators
In addition to the above molecules, several additional mediators are produced 
by MSCs or other adult stem/progenitor cells upon inflammatory stimulation, such 
as the inhibitory surface protein programmed death ligand 1 (PD-L1) [54], heme 
oxygenase-1 (HO-1) [55], leukemia inhibitory factor (LIF), galectins [56], and 
TGF-β [57]. However, their modes of action and underlying molecular mechanisms 
that drive MSC-mediated immunosuppression require further investigation.
3.7 Molecular and cellular interaction of MSCs with innate and acquired  
immune cells
3.7.1 MSC interaction with T and B cells
The antigen-specific immune system allows the development of immunological 
memory. It comprises of CD4+ T helper and CD8+ cytotoxic T lymphocytes that 
deliver a customized antigen-specific immune response following antigen process-
ing and presentation by antigen-presenting cells (APCs). T helper cells comprise 
a subpopulation of cells called Tregs, which are specialized in suppression of T 
cell-mediated immune response [58]. The innate immune system plays an important 
role in the activation and subsequent course of adaptive immune response [59]. In 
addition, MSCs are able to suppress in vitro T-cell proliferation induced by cellular 
or non-specific mitogenic stimuli through the secretion of various soluble factors 
that include (transforming growth factor-beta 1) TGF-β, HGF, PGE-2, IDO, HLA-
G5, and NO. The effect of these suppressive factors is upregulated by pre-sensiti-
zation of MSCs with TNF-α and IFN-γ. It is also known that MSCs polarize T cells 
toward a regulatory phenotype that serves as an important mechanism by which 
MSCs dampen inflammation [60, 61]. Tregs comprise a subpopulation of T helper 
cells, which are specialized in suppression of T cell-mediated immune response and 
characteristically express the forkhead box P3 (Fox P3) transcription factor. These 
are two main subsets of Tregs including a population of Fox P3+ natural Tregs 
which are thymus derived and specific for self-antigen and induced or adaptive 
Tregs that are derived from mature CD4 + CD35-FoxP3 precursors in the periphery 
following inflammatory stimuli. The in vitro co-culturing of MSCs with PBMNCs 
induced the differentiation of CD4+ T cells into CD25 + FoxP3+ expressing regula-
tory T cells [40, 62]. The possible reason of abovementioned mechanism is due to 
cell-cell contact of MSCs with helper T cells and secretion of PGE-2 and TGF-β. All 
together, these studies indicate that MSCs are able to maintain the balance between 
inflammatory effector T cells and anti-inflammatory Tregs.
B cells are also a major cell type involved in adaptive immune response, known 
for antigen presentation and antibody production. The balance between the 
different B-cell subsets has been identified as an important factor for optimal 
graft outcomes. To support the beneficial effect of B-cell depletion at the time of 
transplantation to impair T cell-mediated allo-response, the CD8 and CD4 T-cell 
memory is impaired when the antigen-presenting function of B cells is absent [63]. 
The exposure of enriched B-cell population to irradiated third party PBMNCs led to 
an increase in immunoglobulin (Ig) production that was abrogated by the addition 
of MSCs. There are diverse results among the studies to analyze the effect of MSCs 
upon exposure of isolated pure B cells [64]. These effects have been shown to be 
cell-cell contact independent or indirect through inhibition of pDC-induced B-cell 
maturation. On exposure, MSCs increased the viability of B cells and mediated 
the arrest of cell cycle at G0/G1 and inhibition of their differentiation into plasma 
cells and subsequent Ig formation, whereas it was observed that pre-treatment of 
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MSCs with IFN-γ was necessary for their suppressive effect on B cells [66]. The 
activated B cells and memory B-cell subsets when exposed to MSCs were seen to 
increase their survival and proliferation [65]. The studies carried out by Schu et al. 
[66] showed that when allogeneic MSCs were injected into rats, a strong humoral 
response was elicited as compared to injection with syngeneic cells in an immuno-
competent host.
To support whether the allogeneic MSCs exert a humoral response in the recipi-
ent to prove the notion, they performed the experiment in which a rat was injected 
with allogeneic MSCs; on the other hand, contradictory reports were also published 
stating after transplantation none of them developed anti-MSC antibodies [66]. 
These studies indicate some disparity of humoral response directed against the 
injected MSCs, and possible reasons may be the source of MSCs, number of injected 
cells and frequency of injections, route of administration, or concurrent immuno-
suppression used.
3.7.2 MSC interaction with NK cells
Natural killer cells or NK cells are a type of cytotoxic lymphocytes critical to the 
innate immune system, evolve as progenitors in the bone marrow, and circulate as 
mature cells in the blood. They provide rapid responses to viral-infected cells, act-
ing 3 days after infection, and respond to tumor formation. They play a major role 
in the mechanisms of rejection of graft and are central to the regulation of cytotox-
icity in response to human leukocyte antigen molecule. With increasing trends in 
therapeutic usage of MSCs for treatment of GvHD, it is important to investigate the 
underlying effects of interaction of MSC and NK cells. They function in the manner 
that they get activated and inhibited on cell surface because of receptors transmit-
ting the signal into the cell. Usually, NK cell possesses regulatory functions and can 
secrete cytokines and chemokines which modulate the host’s immune response. 
IL-12 is the most important pro-inflammatory factor which responds to penetrating 
pathogens and acts through its high affinity receptors. It is released from accessory 
cells like monocytes, macrophages, and dendritic cells (DCs). Also, the most impor-
tant cytokine released by NK cells is IFN-γ which is produced upon stimulation of 
IL-12. The NK cell-derived IFN-y reinforces the expression of IL-12 and DCs via 
feedback mechanism. BM-MSCs directly interfere with the proliferation, cytokine 
production, and in some cases cytotoxicity of NK cells. MSC-NK interactions are 
complex and largely dependent on the microenvironment and activation status of 
the NK cells. Mainly, MSCs suppress the production of IL-2, IL-15, and INF-γ but 
not the cytotoxicity of freshly isolated NK cells. In addition, when activated NK 
cells come into contact with the MSCs, it interferes with NK-mediated cytotoxicity 
which is primarily mediated by cell-cell contact and secretion of IDO, PGE-2, TGF-
β1, and HLA-G5. Other reports mentioned that when licensed MSCs were exposed 
to IFN-γ, they are protected from NK-mediated cell killing, potentially due to their 
upregulated cell surface expression of HLA-I and downregulation of ULBP-3. This 
alongside an increased production of both IDO and PGE-2 offers multiple mecha-
nisms for dampening NK responsiveness to the MSCs [59, 67, 68].
3.7.3 MSC interaction with dendritic cells
The potent antigen-presenting cells (APCs) and dendritic cells (DCs) play a piv-
otal role in initiating immune response. The life span of DCs can be divided into two 
major phases, an immature stage and a mature stage. These phases can be differenti-
ated further on the basis of molecules expressed (CD80, CD86, OX62, HLA-II, and 
CD11b/c) on their surface. DCs can be immunostimulatory or immunosuppressive, 
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depending upon their maturation stage and specific DC subset. Immature DCs 
(iDCs) express low levels of HLA-II but no co-stimulatory molecules. The interac-
tion of MSCs with DCs leads to the inhibition of maturation of monocytes and 
CD34+ precursor cells. Moreover, the direct activation of DCs leads to the release of 
PGE-2, IL-6, TSG-6, MCSF, and jagged-2 mediated signaling. Tolerogenic pheno-
type occurs when DC secretome of pro-inflammatory cytokines (TNF-α and IL-12) 
shifts toward anti-inflammatory IL-10 in which further downstream induces Th2 
and Treg responses [69–71].
4. Paracrine interaction with in the niche (exosomes)
Advances in stem cell technology have opened interesting perspectives within 
the realm of regenerative medicine. As reported, MSCs participate in repair and 
regenerative processes via different mechanisms like homing and transdifferentia-
tion and immunomodulation, which depends on paracrine mechanisms [72, 73]. 
The initial studies using MSCs were based on local engrafting of MSCs and dif-
ferentiating into multiple tissue types. However, with the in-depth study of dif-
ferent mechanisms of MSC action, it has been reported that <1% MSCs are able to 
survive transiently after systemic administration [74]. This suggests that paracrine 
mechanisms through secretion of various molecules called secretome might be the 
possible mechanism for MSC regenerative potential. This has attracted significant 
attention for the potential use of MSC secretome in tissue repair and regeneration.
The secretome released by MSCs includes various biologically active growth 
factors and cytokines which aid in immunomodulatory properties of MSCs [75]. 
However, we cannot neglect the fact that the secretome released in the milieu of 
ECM of the cells is an easy target for denaturation due to the presence of proteases 
and other enzymes in the microenvironmental niche. Therefore, these growth fac-
tors and cytokines have been shown to be packed into small vesicles called exosomes 
which are secreted by MSCs in the extracellular milieu of cell along with the 
secretome [76]. They function through encapsulation of biological active molecules 
such as miRNA, proteins, and immunomodulatory molecules and protect them 
from degradation.
4.1 Exosome formation to secretion
Exosomes are lipid membrane-bound extracellular vesicles which possess a 
diameter of 30–120 nm and a density of 1.09–1.18 g/mL and are secreted by all cell 
types. These exosomes carry cellular components like proteins and nucleic acids 
and aid in cell-cell communication. The exosome was first discovered in 1984 by 
Johnstone in sheep reticulocytes [77]. It was initially believed that exosomes remove 
unwanted proteins from cells. Later on, it was demonstrated that many other cell 
types also secrete exosomes including immune cells, cancer cells, stem cells, and 
many more [78].
Exosomes are endosomal in origin, formed within multivesicular endosomes 
(MVEs). These vesicles are being released when membranes of MVEs fuse with that 
of the cellular plasma membrane. These exosomes express various surface markers 
like CD63, CD81, and CD9. They carry surface molecules that are present on the 
parent cell which aids in identification of exosomes and their parent cell source as 
well [77].
Moreover, the exosomes secreted by stem cells carry various proteins (growth 
factors and cytokines) and nucleic acids (mRNA and miRNA) that can influence 
their mode of action [79]. The content carried by these vesicles depends on the type 
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of cell (including source of cells) and its state of activation. Once released, these 
vesicles have local as well as remote effect by interacting with the neighboring cells 
or by circulating in the body fluids (bloodstream, saliva, serum, etc.).
4.2 Exosomes and immune cells
The exosomes were studied for their multifaceted application in antigen presen-
tation, and vastly studied immune cell was dendritic cells. The clinical studies have 
been conducted to evaluate the dendritic cell derived exosomes for their therapeutic 
potential. However, compared to preclinical studies, only a few clinical trials have 
been conducted using exosomes. Reported studies were conducted where dendritic 
cell-derived exosomes were evaluated for their safety, tolerability, and efficacy in 
cancer patients. Exosomes carry parental cell surface marker expression. In this 
regard, DC derived exosomes are HLA-II positive as a result they can only be used 
in patient specific studies [80, 81]. In contrast, MSCs are immunologically naïve as 
they express only HLA class I molecules and lack HLA class II, CD40, CD80 and 
CD86 expression on their cell surface. Also, they are capable of immune escape and 
fail to induce an immune response by the transplanted host. Similarly, exosomes 
secreted by them are also immunologically naïve [82]. Considering all of the above 
properties, several recent studies have focused their research on evaluation of stem 
cell-derived exosomes in the area of immunomodulation with fewer reports.
In a recent study, exosomes derived from MSCs were specifically identified to 
mimic the effect of MSCs, and this paved the way to cell-free therapeutic approach 
using exosomes instead of the cell itself [83]. The first report using MSC exosomes 
were in cardiovascular diseases where Lai et al. [85] identified exosomes as the 
cardioprotective components in MSC paracrine secretion [84]. This was followed 
by several other studies where exosomes isolated from tissue-specific MSCs were 
studied for their therapeutic potential in various diseases.
Initial studies were performed on bone marrow-derived exosomes for evalu-
ating their regenerative potential in cardiovascular diseases [85], acute kidney 
injury [86], bone defects, etc. [87]. By 2013, only researchers started exploring 
the regenerative potential of exosomes derived from adipose tissue and Wharton’s 
jelly sources. These studies have explored the various mechanisms by which these 
exosomes mimic MSCs. The content of these exosomes was evaluated by using vari-
ous techniques like RNA sequencing, mass spectrometry, etc., to identify different 
molecules and their target effect.
Conforti et al. reported the effect of MSC-derived vesicles on B-cell prolifera-
tion which was further confirmed by Di Trapani’s group in 2016 [88, 89] . They 
observed that exosomes had higher levels of miRNAs compared to MSCs and induce 
inflammatory priming via increasing levels of miR-155 and miR-146. These are 
two miRNAs involved in the activation and inhibition of inflammatory reactions. 
Similar studies were reported where MSC-derived exosomes were shown to increase 
the ratio between regulatory and effector T cells along with the increase in cytokine 
such as IL-10 [90]. Similarly, Chen et al. [91] has also reported immunomodula-
tory effects of MSC-derived exosomes toward peripheral blood mononuclear cells 
(PBMNCs) focusing specifically on T cells. It was observed that there was signifi-
cant inhibition of pro-inflammatory cytokines, IL-1β and TNF-α, but enhancement 
of the expression of anti-inflammatory cytokine, TGF-β1. This cytokine profile 
in their study mimics the immunomodulatory effect of MSCs [91]. Zhang et al. 
showed that these exosomes may polarize monocytes toward M2-like phenotype, 
which in turn induces CD4+ T-cell differentiation into regulatory T cells [92].
Blazquez et al. demonstrated AD-MSC-derived exosomes as a therapeutic agent 
for the treatment of inflammation-related diseases. They showed that exosomes 
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exerted an inhibitory effect on the differentiation of activated T cells, reduced 
T-cell proliferation, and IFN-γ secretion in an in vitro stimulated T-cell model 
[93]. Favaro et al. has shown the effect of BM-MSC-derived exosomes on PBMNCs 
isolated from type I diabetic patients. These exosomes were able to inhibit the IFN-γ 
production and significantly increased the production of immunomodulatory 
mediators such as PGE-2, TGF-β, IL-10, and IL-6 [94]. The in vitro studies were 
complemented by the in vivo studies which confirmed the immunosuppressive 
effect of exosomes in mouse allogeneic skin grafting models [95]. Bai et al 2017 have 
subcutaneously administered exosomes isolated from human embryonic stem cell-
derived MSCs and showed that there was delayed occurrence of GvHD for 2 days, 
concomitant with increasing Treg polarization. In continuation, the author has also 
demonstrated that exosomes released from WJ-MSCs can effectively ameliorate 
experimental autoimmune uveoretinitis (EAU) in rats by inhibiting the migration 
of inflammatory cells [95]. Moreover, there is only single case study on humans in 
which MSC exosomes have been tested in the treatment of resistant grade IV acute 
GvHD patient which experienced improvement in symptoms for 5 months. There 
were no side effects reported, and the decrease of pro-inflammatory cytokines 
such as TNF-α, IL-1β, and IFN-γ was observed. The anti-inflammatory molecules 
IL-10, TGF-β1, and HLA-G contained in the exosome preparations were believed to 
contribute to the immunosuppressive effect of MSC-Exo [96].
Although there are limited studies available using MSC-derived exosomes, 
future advancements into research and gain in in-depth knowledge of immuno-
modulatory properties of these MSC exosomes could be seen. These nano-vesicles 
can be developed as cell-free therapies. The use of these exosomes as cell-free 
therapies provides following key advantages:
a. Less tumorigenicity.
b. Easy storage without application of potentially toxic cryopreservative agents.
c. Mass production through tailor-made cell lines.
d. Potential to be used as ready-to-go biologic product.
e. Off-the-shelf secretome therapies.
f. The time and cost of expansion and maintenance could be greatly reduced.
g. The biological product obtained could be modified to desired cell-specific 
effects.
Despite these advantages of MSC-derived exosomes, there has been a lack of 
manufacturing process that is required to generate exosomes with clinically relevant 
quantities. Therefore, there is an urgent need for technological advancements. 
Nevertheless, regulatory requirements will be necessary to establish the safety and 
efficacy profile of these exosome products.
5. MSCs in preclinical and clinical trials
MSCs delivered alone or with a biomaterial have been used in a variety of 
regenerative medicine strategies. In vivo evidence supports the hypothesis that 
MSCs have immunosuppressive properties that include prevention of graft versus 
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host disease (GvHD), decreased graft rejection, prevention of experimental acute 
encephalomyelitis, prolonged skin graft survival, etc. [8]. However, in recent 
years, consistent reports on its immunomodulatory properties have opened 
up newer avenues for studying MSCs, other than regenerative medicine. As of 
May 2018, there were over 843 MSC-related clinical trials registered on the NIH 
Clinical Trial Database (http://clinicaltrial.gov/). Interestingly, half of all regis-
tered clinical trials (~45%) are being conducted for immune-mediated diseases. 
Of these, 69 are based on autoimmune disease, 38 on GVHD, and the rest 290 
on other inflammatory diseases. However, in early phase I, phase II, phase III, 
and phase IV, there were 3, 76, 7, and 6 clinical trials conducted, respectively. 
Hematopoietic stem cells (HSCs) have been the most successful in providing 
therapeutic application using stem cells. MSCs represent a lifesaving treatment 
for patients suffering with hematopoietic malignancies and genetic diseases. HSC 
transplantation is performed either autologous or with matched allogeneic/third 
party, depending upon the clinical scenario. Furthermore, in allogenic transplan-
tation, immunosuppression is necessary to reduce the graft rejection in patients. 
But despite immunosuppressant therapy, immune rejection in the form of GvHD 
is still a major cause of morbidity and mortality. The clinical application of MSCs 
for GvHD developed more rapidly than for any other immune-mediated diseases 
[68]. The probable cause could be case reports in severe GvHD where BMSCs were 
infused and showed dramatic therapeutic effects. Clearly, MSCs have a strong 
potential as therapeutic agents for GvHD, but detailed tailoring of patient popula-
tion and stringent MSC processing criteria are necessary to deliver consistent and 
reproducible results [97–100].
Apart from GvHD condition, multiple sclerosis (MS), joint diseases such as 
osteoarthritis (OA) and rheumatoid arthritis (RA), inflammatory bowel diseases 
(IBD) and inflammatory airway, and pulmonary diseases are few examples of 
inflammatory diseases in which preclinical studies have established strong thera-
peutic effect of MSCs [101]. In multiple sclerosis, reports showed that MSC treat-
ment increases accumulation of Th2 cytokines-IL-4 and IL-5 and generation of 
Treg in vivo both of which help reduce EAE symptomatology. The possible molecu-
lar mechanism by which MSCs polarize CD4 T cells in EAE is via IDO. Indeed, both 
small and large animal studies demonstrate that MSCs decrease inflammation in 
joint diseases and facilitate cartilage repair [102].
The critical part of IBD is the uncontrolled immune response to intestinal 
microbes, and it is progressively fatal without curative treatment, making MSCs 
an attractive therapeutic option for these chronic inflammatory diseases. In several 
experimental models of IBD, MSCs given by intraperitoneal or intravenous routes 
showed prevention of DSS-induced injury of the intestines. It was observed that MSCs 
can specifically reduce Th1 and Th17 responses as well as serum level of pro-inflam-
matory cytokines (IL-1b, IL-6, IL-17, TNF-α, and IFN-γ) while enhancing the num-
bers of Tregs and splenic (myeloid-derived suppressor cells) MDSCs. A very recent 
trial using allogeneic placenta-derived MSC-like cells (which were not registered) also 
showed favorable immune responses. Thus, MSC therapy for IBD—especially CD 
fistula formation—appears to be safe and a viable option [103, 104].
Pulmonary diseases like chronic obstructive lung disease (COPD) are driven 
by alveolar macrophages, cytotoxic T cells, and neutrophils leading to progressive 
limitations in airflow with small airway fibrosis and alveolar destruction. In in vivo 
studies documented post-MSC infusion showed downregulation of pro-inflam-
matory cytokines such as TNF-α, IL-1β, and IL-6 and upregulation of VEGF and 
TGF-β [105, 106]. In addition, MSCs or MSC-conditioned medium improved tissue 
damage and survival. This involves MSC-derived factors with microvesicles such as 
exosomes, which are considered as carriers.
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6. Conclusion
MSCs are excellent candidates for therapeutic use as cellular therapies can 
potentially revolutionize the current pharmaceutical landscape. Emerging data sug-
gests that MSCs have an immunomodulatory function, but thorough understanding 
of the mechanisms underlying the complex molecular interplay between MSCs and 
inflammatory responses will be crucial for exploiting MSC-based therapies in ther-
apeutic applications. One important aspect is to delineate functional differences 
in tissue-specific MSCs isolated from different sources; current ISCT standardiza-
tion does not include immune-related functional tests or more detailed molecular 
validation. Based on the evidence of several clinical trials, the safety of this therapy 
appears clear; however, the efficacy of such cell therapy is largely uncertain. The 
overwhelming positive results seen in preclinical animal studies have not yet been 
translated into clinic. In brief, there is still much to learn, explore, and optimize 
with regard to the interactions of MSCs in human pathological conditions. In the 
near future, based on current development and results, MSCs are expected to hold 
tremendous potential to achieve clinical relevance in regenerative therapy.
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